Sibel Health Cough Sensor Accepted Into FDA Drug Development Tool Program

According to a recent LinkedIn post from Sibel Health, the company’s Aria cough monitoring sensor has been accepted into the FDA Drug Development Tool Clinical Outcome Assessment Qualification Program. The post highlights this as the third such acceptance for Sibel Health, positioning Aria as a tool for objective, privacy-preserving cough measurement in chronic refractory cough.

The LinkedIn post suggests that Aria’s ability to deliver real-time cough detection without recording identifiable audio may lower burden for patients and researchers while addressing unmet needs in respiratory health trials. For investors, repeated FDA DDT COA acceptances could enhance Sibel Health’s credibility with biopharma sponsors, potentially strengthening its role in clinical trials and supporting longer-term revenue opportunities in digital health and wearable-enabled drug development.